JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallego, O.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallego, O.
Right arrow Articles by Soriano, V.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2003, p. 1245-1247, Vol. 41, No. 3
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.3.1245-1247.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients

Oscar Gallego, Carmen de Mendoza, Angélica Corral, and Vincent Soriano*

Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain

Received 29 August 2002/ Returned for modification 4 November 2002/ Accepted 15 December 2002


   ABSTRACT
Top
 Abstract
Text
 References
 
Resistance to antiretroviral agents often results from mutations within the human immunodeficiency virus (HIV) pol gene. Moreover, insertions within the p6 gag-pol region have recently been found to be involved with resistance to nucleoside analogs. Overall, we found that 21% of 156 specimens collected from HIV-infected individuals (17.6% from 74 drug-naive patients and 24.4% from 82 pretreated patients) harbored these insertions. Insertions around the KQE (Lys-Gln-Glu) motif were found in 12.2% of the pretreated patients but in none of the drug-naive subjects (P = 0.002). In contrast, insertions around the PTAP (Prol-Thre-Ala-Prol) motif were seen at similar rates (~15%) among drug-naive and pretreated patients, which supports the idea that they may be natural polymorphisms.


   TEXT
Top
 Abstract
 Text
References
 
Combination drug regimens consisting of reverse transcriptase (RT) and protease inhibitors (PIs) have proven to be highly effective in suppressing human immunodeficiency virus (HIV) replication for a sustained period of time (2; www.hivatis.org). However, the effectiveness of these therapies is often blunted after the emergence of drug-resistant viruses, which frequently show extensive cross-resistance within each drug class (4, 5, 10, 11).

Reduced sensitivity to antiretroviral drugs may be associated not only with mutations within protease and RT genes but also with genotypic changes at the p6gag region localized immediately upstream of the pol gene (Fig. 1) (13, 16). Changes in the p6 region lead to a complex viral phenotype that includes increased infectivity and resistance to nucleoside analog RT inhibitors (NRTIs) and PIs. Insertions in the p6 region have been associated with loss of susceptibility to NRTIs, particularly with loss of susceptibility to stavudine (d4T), zalcitabine, and didanosine (ddI). This is of particular interest given our limited understanding of the mechanisms of HIV type 1 resistance to d4T and ddI (3, 14).



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 1. The HIV p7-p1-p6 genomic region. TF, trans frame; MA, matrix; CA, capsid; NC, nucleocapsid.

 
In this study, we evaluated the rate and conditions of selection of insertions within the p6 region. All plasma samples referred to our reference laboratory for drug resistance testing during the last trimester of 2001 were examined. They belonged to HIV-infected individuals attending several HIV clinics across Spain. At the time of analysis, all samples had viral loads of >1,000 HIV RNA copies/ml. Genotypic analyses were performed by using an RT-PCR with C35 (5'-AAGAAATGATGACAGCATGTCAGGGAGTAGGAGGA-3') and NE135 (5'-CTTACT AACTTCTGTATGTCATTGACAGTCCAGCT-3') as outer primers. A nested PCR was then performed with DP15 (5'-AAGGGCTGTTGGAAATGTGG-3') and DP17 (5'-AAAATTTAAAGTGCAGCCAAT-3') as inner primers. Genetic sequencing was performed with an ABI Prism 3100 automated sequencer (Applied Biosystems, Foster City, Calif.). Consensus sequences for the virus population were aligned with those belonging to HIV type 1 HXB2.

Genotypic results were obtained from 156 specimens, 74 of which were collected from drug-naive individuals and the remaining 82 of which were collected from patients on antiretroviral therapy. Both insertions and deletions were identified in the p7-p1-p6gag region. A total of 33 subjects (21%) carried viruses with insertions in the p6gag region. They were found in 13 (17.6%) of 74 samples from drug-naive subjects and in 20 (24.4%) of 82 treatment-experienced patients (no statistically significant difference). Insertions were recognized preferentially in the first 11 amino acids, involving the polyproline motif PTAP (Pro-Thre-Ala-Prol), and between amino acids 24 and 34, including the KQE (Lys-Gln-Glu) motif, of the p6 protein (Fig. 1).

The duplication of the PTAP motif appeared at similar rates among drug-naive and pretreated individuals (13 [17.6%] versus 10 [12.2%], respectively), which supports the idea that it may be a natural polymorphism (W. Dong, Z. Brumme, K. Chan, R. S. Hogg, V. O'Shaughnessy, J. Montaner, and P. R. Harrigan, 9th Conf. Retrovir. Opportunistic Infect., abstr. 572-T, p. 265; D. Smith, S. J. Little, E. S. Daar, R. Koup, N. S. Hellmann, K. Dawson, J. W. Wong, D. Richman, and A. J. Leigh Brown, 9th Conf. Retrovir. Opportunistic Infect., abstr. 357-M, p. 189). In contrast, duplications of the KQE motif of the p6gag protein were found in 10 samples (12.2%) belonging to antiretroviral therapy-experienced subjects but in none from drug-naive individuals (P = 0.002).

Nearly 80% of samples from treatment-experienced patients showed resistant genotypes at the pol gene, a rate similar to that reported in previous studies conducted with subjects whose antiretroviral treatment failed (6, 7, 15). All samples harboring insertions within the p6gag region showed classical mutations associated with resistance to PIs (median of 7 [range, 4 to 9] mutations in the PRO gene) and to NRTI (median of 7 [range, 4 to 12] mutations in the RT gene). All of these subjects had been extensively exposed to antiretroviral drugs for a median of 77 (range, 53 to 108) months.

Extensive polymorphisms were observed in the gag region throughout the p7, p1, and p6 proteins. However only four point mutations localized immediately upstream of the pol gene, in the cleavage sites, were more frequently found among treatment-experienced subjects (Table 1). The A54I/V mutation in the p7 region appeared in 14 pretreated patients but in only 1 drug-naive patient (17 versus 1.3%; P = 0.001). This change appeared to be associated with specific PI resistance mutations, such as L90M in nine (64.3%), V82A/F/T in eight (57%), and M46I/L in seven (50%) of the cases, respectively. On the other hand, the I5F/L/V change in the p1 region was found in 14 treatment-experienced patients and in 4 drug-naive patients (17 versus 5.4%; P = 0.023). This amino acid substitution appeared in 71.4% of samples associated with L90M, a key PI resistance mutation. These findings are in agreement with those of Bally et al. (1). Finally, two other substitutions in the p6 region were associated with exposure to antiretroviral agents; P5I/L/T and E20A/G/K were found in 34 and 8.5% of the pretreated subjects but in 11% and none of the drug-naive subjects, respectively (P = 0.001 and 0.01, respectively). Both mutations in p6 were associated with L90M at the PRO gene (46.4 and 85.7% of the cases, respectively). Overall, the recognition of a significant association between mutations at gag cleavage sites and primary PI resistance mutations supports the concept that they serve as compensatory changes increasing the kinetics of virus-mutated proteases and therefore contributing to enhance PI resistance (16, 17).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Insertions in the p6gag region and mutations at cleavage sites in antiretroviral-naive and pretreated HIV-infected patients

 
Peters et al. (13) reported recently that the presence of duplications in the polyproline (PTAP) motif was associated with exposure to antiretroviral drugs, mainly with exposure to d4T and ddI. Hypothetically, viruses with insertions in the PTAP motif could package an excess of RT enzymes and, by an inoculum effect, cause loss of phenotypic susceptibility to all NRTIs, although to different extents (d4T > zalcitabine > ddI > zidovudine > abacavir). This circumstance could be explained by the different effective intracellular concentrations achieved by these compounds, which, for some drugs, are only marginally above the level necessary to inhibit virus replication (13).

In our study, we did not find an association between PTAP motif duplications and more frequent current or past exposure to d4T and/or ddI. In contrast, insertions in the PTAP motif appeared at similar rates among drug-naive and pretreated patients, independently of the treatment regimen. Similar results have been reported recently by others (4; Smith et al., 9th Conf. Retrovir. Opportunistic Infect.). Therefore, PTAP duplications may more appropriately be considered natural polymorphisms rather than drug-resistant genotypes.

In contrast, we found insertions between amino acids 24 and 34 in the p6gag region in 10 treatment-experienced patients but in none of the drug-naive patients (P = 0.002). We further analyzed the influence of d4T and/or ddI on the development of these insertions within the KQE motif of the p6 protein and found no relationship. The presence of insertions in the C-terminal end of the p6gag protein could have therapeutic implications, increasing drug resistance to a wide range of antiretrovirals drugs. Accordingly, preliminary data from Kaufmann et al. (9) have recently underlined the fact that alterations in the C-terminal end of the p6gag protein contributed to the failure of a quadruple regimen including two NRTIs plus saquinavir and ritonavir.

The analysis of specific associations between gag cleavage site polymorphisms and particular PRO substitutions provides additional evidence of the demands of adapting a mutated active protease site to a modified cleavage site. It is worth noting that mutations at cleavage sites are mainly selected in the presence of protease mutations at residue 90 and less frequently in the presence of mutations at codons 46 and 82.

In conclusion, insertions in the p6gag region appear in a significant proportion (21%) of HIV-infected individuals. Duplications in the PTAP region appear to be much more common (17.6%) in drug-naive individuals than previously reported. Only insertions in the KQE motif in the p6 protein, as well as point mutations at codon 54 in the p7 protein, codon 5 in the p1 protein, and codons 5 and 20 in the p6 protein, are significantly associated with exposure to antiretroviral drugs. The implications of these gag mutations for HIV drug resistance and antiviral therapy failure need to be further investigated.


   ACKNOWLEDGMENTS
 
We thank Juan González-Lahoz for continuous support.

This work was funded in part by grants from the Asociación Investigación y Educación en SIDA (AIES), the Comunidad Autónoma de Madrid (CAM), and the Instituto de Salud Carlos III.


   FOOTNOTES
 
* Corresponding author. Mailing address: C/Nueva Zelanda 54, 4° B, 28035 Madrid, Spain. Phone: 34-91-4532500. Fax: 34-91-7336614. E-mail: vsoriano{at}dragonet.es. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Bally, F., R. Martinez, S. Peters, P. Sudre, and A. Telenti. 2000. Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 16:1209-1213.[CrossRef][Medline]
  2. Carpenter, C. J., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. Gazzard, S. M. Hammer, M. S. Hirsch, D. Jacobsen, D. A. Katzenstein, J. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. Schooley, M. A. Thompson, S. Vella, P. Yeni, and P. Volberding. 2000. Antiretroviral therapy in adults: update recommendations of the International AIDS Society-USA Panel. JAMA 283:381-390.[Abstract/Free Full Text]
  3. Coakley, E. P., J. M. Gillis, and S. Hammer. 2000. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15.[CrossRef][Medline]
  4. Deeks, S. 2001. International perspectives on antiretroviral resistance: nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):25-33.
  5. De Mendoza, C., V. Soriano, C. Briones, O. Gallego, P. Barreiro, A. Alvarez, and J. González-Lahoz. 2000. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J. Acquir. Immune Defic. Syndr. 23:279-281.
  6. Gallego, O., L. Ruiz, A. Vallejo, E. Ferrer, A. Rubio, B. Clotet, M. Leal, V. Soriano. 2001. Changes in the rate of genotypic resistance to antiretroviral drug in Spain. AIDS 15:1894-1896.[CrossRef][Medline]
  7. Gómez-Cano, M., A. Rubio, T. Puig, M. Pérez-Olmeda, L. Ruiz, V. Soriano, J. A. Pineda, L. Zamora, N. Xaus, B. Clotet, and M. Leal. 1998. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 12:1015-1020.[CrossRef][Medline]
  8. Hirsch, M., F. Brun-Vézinet, R. D'Aquila, S. M. Hammer, V. A. Johnson, D. Kuritzkes, C. Loveday, J. Mellors, B. Clotet, B. Conway, L. Demeter, S. Vella, D. Jacobsen, and D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV infection. JAMA 283:2417-2426.[Abstract/Free Full Text]
  9. Kaufmann, G. R., K. Suzuki, P. Cunningham, M. Mukaide, M. Kondo, M. Imai, J. Zaunders, and D. A. Cooper. 2001. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res. Hum. Retrovir. 17:487-497.[CrossRef][Medline]
  10. Loveday, C. 2001. International perspectives on antiretroviral resistance: nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):10-24.
  11. Miller, V. 2001. International perspectives on antiretroviral resistance: resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. 26(Suppl. 1):34-50.[CrossRef]
  12. Perrin, L., and A. Telenti. 1998. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280:1871-1873.[Abstract/Free Full Text]
  13. Peters, S., M. Muñoz, S. Yerly, V. Sanchez-Merino, C. López-Galindez, L. Perrin, B. Larder, D. C. Marko, S. Fakan, P. Meylan, and A. Telenti. 2001. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by HIV type 1 p6 protein. J. Virol. 75:9644-9653.[Abstract/Free Full Text]
  14. Petropoulos, C., N. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for a HIV type 1. Antimicrob. Agents Chemother. 44:920-928.[Abstract/Free Full Text]
  15. Puig, T., M. Pérez-Olmeda, A. Rubio, L. Ruiz, C. Briones, J. M. Franco, M. Gómez-Cano, L. Stuyver, L. Zamora, C. Alvarez, M. Leal, B. Clotet, and V. Soriano. 2000. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 14:727-732.[CrossRef][Medline]
  16. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in HIV type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.[Abstract/Free Full Text]
  17. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites. J. Virol. 71:6662-6670.[Abstract]

Journal of Clinical Microbiology, March 2003, p. 1245-1247, Vol. 41, No. 3
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.3.1245-1247.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallego, O.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallego, O.
Right arrow Articles by Soriano, V.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS